Occam is pleased to announce the placement of Vijay Reddy, MD as Chief Research & Development Officer of Tmunity Therapeutics, a private, clinical-stage, oncology-focused cell therapy company that has raised over $200M from topflight investors including Kleiner Perkins, Lilly Ventures and Gilead.

In Vijay, Tmunity captures a seasoned and entrepreneurial drug developer steeped in oncology with domain expertise in cell therapy.

Reddy has significant experience in cancer research including immuno-oncology, having started his career as a medical oncologist at MD Anderson Cancer Center. He subsequently developed the CAR-T cell clinical program with first-in-class targets in his most recent role with Autolus and played a critical role bringing new therapies to market at Janssen Pharmaceutical Companies and GlaxoSmithKline